NCT00003497View on ClinicalTrials.gov

Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 21, 1996

Primary Completion Date

February 2, 1998

Study Completion Date

February 2, 1998

Conditions
Stage IV Non-small Cell Lung Cancer
Interventions
DRUG

Antineoplaston therapy (Atengenal + Astugenal)

Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.

Trial Locations (1)

77055-6330

Burzynski Clinic, Houston

Sponsors
All Listed Sponsors
lead

Burzynski Research Institute

OTHER